
FDA Fast Tracks Onvansertib for First-Line RAS-Mutated mCRC
Key Takeaways
- FDA fast track status supports accelerated development of oral, selective PLK1 inhibitor onvansertib combined with FOLFIRI/bevacizumab for first-line RAS-mutated mCRC, a setting lacking targeted approvals.
- Interim CRDF-004 intent-to-treat data showed confirmed ORR 72.2% with onvansertib 30 mg plus FOLFIRI/bevacizumab versus 42.1% with FOLFIRI/bevacizumab alone, a 30.1-point gain.
The designation supports development of onvansertib plus FOLFIRI/bevacizumab as first-line therapy for KRAS- or NRAS-mutated metastatic colorectal cancer, based on phase 2 CRDF-004 findings.
The FDA has granted fast track designation to investigational drug onvansertib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab (Avastin) for the first-line treatment of adults with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC), providing an expedited regulatory pathway for the regimen as clinical development advances. The designation is supported by findings from the ongoing randomized phase 2 CRDF-004 trial (NCT06106308).¹
In the intent-to-treat population, the proposed registrational regimen of onvansertib 30 mg plus FOLFIRI/bevacizumab demonstrated a confirmed objective response rate (ORR) of 72.2% compared with 42.1% with FOLFIRI/bevacizumab alone. This represented a 30.1-percentage-point improvement in confirmed ORR. Additionally, median progression-free survival (PFS) had not been reached in the 30-mg onvansertib combination arm as of September 28, 2026, compared with approximately 11 months in the combined standard-of-care (SOC) arms.
“Patients with
For
PLK1 is involved in cell-cycle regulation and mitotic progression. Inhibition of this kinase is being investigated as a strategy to disrupt cancer-cell division and target tumor vulnerabilities. Onvansertib is also being evaluated in investigator-initiated studies involving metastatic pancreatic ductal adenocarcinoma, triple-negative breast cancer, chronic myelomonocytic leukemia, and small cell lung cancer.
Phase 2 CRDF-004 Findings Support the Registrational Regimen
The randomized, controlled CRDF-004 trial evaluated 2 doses of onvansertib, 20 mg and 30 mg, in combination with FOLFIRI/bevacizumab or fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab against the corresponding SOC chemotherapy regimens in patients with previously untreated RAS-mutated mCRC. The study enrolled 110 patients in its intent-to-treat population and evaluated ORR, PFS, duration of response, and safety.²
The 30-mg onvansertib plus FOLFIRI/bevacizumab regimen was selected for further development based on the totality of the efficacy and safety findings. The 72.2% confirmed ORR compared with 42.1% for FOLFIRI/bevacizumab alone supported the selection of this combination for the registrational program. However, the findings remain preliminary, and the trial is ongoing.
As of September 28, 2026, all patients remaining in the 30-mg onvansertib plus FOLFIRI/bevacizumab arm had received treatment for at least 21 months, with the longest treatment duration exceeding 29 months. Median PFS remained unreached in this group, while median PFS in the combined SOC arms was approximately 11 months.¹
The company also reported that onvansertib was generally well tolerated when added to FOLFIRI/bevacizumab or FOLFOX/bevacizumab in CRDF-004. No apparent differences in the frequency or severity of adverse events were observed between the onvansertib-containing regimens and SOC. Neutropenia was the most common treatment-emergent adverse event among grade 3 or higher events.²
Phase 3 Development Is Planned for 2027
Cardiff Oncology is preparing a registrational phase 3 trial evaluating onvansertib 30 mg plus FOLFIRI/bevacizumab against FOLFIRI/bevacizumab alone as first-line treatment for patients with RAS-mutated mCRC. The planned study, designated CRDF-005, is expected to enroll approximately 640 patients across the US, Europe, and other regions. The trial is designed to evaluate safety and efficacy, with the potential to support accelerated approval based on ORR and full approval based on PFS.³
The company previously indicated that it expects to initiate the registrational study in the first quarter of 2027, subject to securing additional financing. The phase 3 program follows an end-of-phase 2 meeting with the FDA in April 2026, during which the company discussed its development strategy and incorporated agency feedback into the planned study design.³
REFERENCES
1. Cardiff Oncology receives FDA fast track designation for onvansertib in first-line RAS-mutated metastatic colorectal cancer. News release. Cardiff Oncology, Inc. November 16, 2026. Accessed November 16, 2026. https://tinyurl.com/bpdasr9r
2. Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): interim results from the phase 2 randomized CRDF-004 trial. Presented at: 2026 American Society of Clinical Oncology Annual Meeting; June 2026; Chicago, IL. https://www.asco.org/abstracts-presentations/260548
3. Quarterly report on Form 10-Q for the quarter ended September 30, 2026. Cardiff Oncology, Inc. Filed November 12, 2026. Accessed November 17, 2026. https://tinyurl.com/mr2tzfxe
Related to this article








